Fisher Bioservices Inc.

Fisher Bioservices Inc. Clinical Trials Division, a subsidiary of Thermo Electron Corporation (itself under parent Fisher Clinical Services Inc.), operates as a prime contractor providing biorepository, specimen management, cold-chain storage, and pharmaceutical services to federal research agencies across a portfolio of 528 awards (97% prime, 3% sub) with combined potential value of $2.12 billion. The division competes without set-aside restrictions across full-and-open procurements and does not hold SBA certifications.

The division's customer concentration sits heavily with the National Institutes of Health institutes. The top five customer agencies account for 75% of combined potential value, led by the National Institute of Allergy and Infectious Diseases (39 awards, $672.4 million), the National Cancer Institute (82 awards, $550 million), the National Institute of Child Health and Human Development (93 awards, $224.1 million), and the National Institute of Diabetes and Digestive and Kidney Diseases (18 awards, $45.4 million). The Army places an additional 25 awards across the portfolio. By award count, NICHD dominates with 93 awards, but NIAID and NCI anchor most of the dollar value; NICHD's awards carry higher velocity but lower individual value. The division also serves 38 distinct federal agencies overall, including the CDC, Department of Defense (Naval Sea Systems Command, Joint PEO Chemical and Biological Defense), and the FDA through various sub-relationships.

Capability portfolio centers on biospecimen repository management, storage, maintenance, and distribution of biological specimens, cell lines, clinical trial materials, and pharmaceutical compounds across multiple storage environments (ultra-low freezers at −80°C, liquid nitrogen, refrigerated, controlled room temperature). Representative prime work includes a $100 million single-award indefinite delivery contract with NICHD for biospecimen repository services (with numerous task orders for specific studies including FAZST II at $1.78 million, Legacy Collection at $9.58 million, and B Well Mom at $708.9 thousand); a $38.1 million definitive cost-plus-fixed-fee contract with the National Cancer Institute for storage and distribution of clinical agents supporting cancer clinical trials; a $29.4 million definitive contract with NIAID for clinical materials services supporting Division of Microbiology and Infectious Diseases operations; and a $189 million single-award IDC with Naval Sea Systems Command for engineering services and the Naval Occupational Dosimetry System (NODS) with an initial delivery order of $15.4 million. The division also holds a $50 million NIAID indefinite delivery contract for interventional agents chemistry services, a $49.9 million NCATS multiple-award IDIQ for chemistry, manufacturing, and control services supporting drug product development, and a GSA Federal Supply Schedule contract (multiple award, $30.3 million ceiling) for biological specimen and clinical trial services including biorepository management, DNA/RNA extraction, and cell therapy services.

Vehicle position spans the GSA Multiple Award Schedule (174 task orders, $29.8 million combined value), several large single-award indefinite delivery contracts with NIH institutes (NICHD's $100 million biospecimen repository IDC, NCI's $19 million chemical registration and storage IDC, NIAID's $50 million interventional agents chemistry IDC), and multiple-award IDIQs including NCATS' $49.9 million CMC services vehicle and the Navy's $189 million engineering and dosimetry system IDC.

Activity has grown modestly from 14 awards in 2022 to 24 in 2025, with 9 awarded year-to-date in 2026. Sixteen awards carrying combined potential value of $202 million reach ultimate completion in the next twenty-four months, representing significant recompete exposure—particularly the NICHD biospecimen repository IDC task orders and NCI clinical agents storage contract, both of which anchor substantial dollars.

SCI-reported invoicing across federal service contracts above the $150,000 threshold totaled $87.3 million over FY2022–FY2024 ($24.6 million in FY2022, $38.1 million in FY2023, $24.7 million in FY2024). The division's SCI-reported federal workforce trajectory shows 210 FTEs across reported contracts in FY2022, declining to 56.8 FTEs in FY2023 and stabilizing near 62.1 FTEs in FY2024, reflecting contract composition and reporting-threshold changes across that period. On federal services contracts captured in SCI, median government-paid rates ran around $169/hr, with senior labor pricing through $665/hr and entry-level rates from $61/hr. The division self-performs substantially all reported work—across SCI prime records, subcontractors accounted for 0% of total contractor hours, with only two named subcontractors appearing across the prime portfolio, indicating a vertically integrated delivery model.

Subcontract footprint is minimal by design; the division acts as a subcontractor to International Aids Vaccine Initiative Inc. on filovirus vaccine development and storage work (storage and distribution of VSV-SEBOV and VSV-MARV/SUDV drug products and related materials) and to Illumina Inc. on COVID-19 serology testing services including cGMP cell bank storage and analytical support. The division also appears as a sub to Wake Forest University Health Sciences on the Women's Health Initiative Clinical Coordinating Center biorepository task, storing over five million vials in ultra-low freezers with 24/7 monitoring and redundant backup capacity. Grant sub-awards flow through the University of South Florida on National Institute of Diabetes and Digestive and Kidney Diseases supported research—the Environmental Determinants of Diabetes in the Young (TEDDY) study and Type 1 Diabetes TrialNet Data Coordinating Center work—where Fisher Bioservices provides biospecimen repository stewardship.

The division's capability portfolio frames predominantly around NAICS 541380 (Testing Laboratories), with secondary codes in refrigerated warehousing (54180X), research and development in life sciences, and biotechnology. The portfolio shows heavy concentration in laboratory testing services (188 awards), research and development (65 awards), refrigerated storage (58 awards), and health R&D services (84 awards by PSC). Cost-plus-fixed-fee pricing dominates the NICHD and NCI repository work; firm fixed-price applies to GSA schedule delivery orders and smaller logistics tasks. The division has operated as a federal contractor since 2001, positioning itself as specialized infrastructure provider for NIH research operations rather than as a broader scientific services competitor.